Neville Rodie & Shaw’s Whitehawk Therapeutics WHWK Stock Holding History

Neville Rodie & Shaw’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,333	Closed	-$171K	–	254
2022 Q4	$171K	Hold	13,333	–	–	0.02%	245
2022 Q3	$188K	Hold	13,333	–	–	0.02%	240
2022 Q2	$164K	Buy	+13,333	New	+$198K	0.01%	249
2021 Q3	–	Sell	-6,667	Closed	-$169K	–	264
2021 Q2	$169K	Hold	6,667	–	–	0.01%	256
2021 Q1	$129K	Hold	6,667	–	–	0.01%	252
2020 Q4	$98K	Hold	6,667	–	–	0.01%	249
2020 Q3	$150K	Hold	6,667	–	–	0.01%	234
2020 Q2	$125K	Hold	6,667	–	–	0.01%	238
2020 Q1	$55K	Hold	6,667	–	–	0.01%	224
2019 Q4	$62K	Hold	6,667	–	–	0.01%	245
2019 Q3	$68K	Hold	6,667	–	–	0.01%	238
2019 Q2	$91K	Hold	6,667	–	–	0.01%	241
2019 Q1	$90K	Hold	6,667	–	–	0.01%	247
2018 Q4	$170K	Hold	6,667	–	–	0.02%	225
2018 Q3	$309K	Hold	6,667	–	–	0.03%	207
2018 Q2	$415K	Buy	+6,667	New	+$403K	0.04%	180

Other funds holding WHWK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neville Rodie & Shaw's WHWK Position: Q1 2023 in Review

Neville Rodie & Shaw sold out of Whitehawk Therapeutics (WHWK) in Q1 2023, closing a stake of 13,333 shares — an estimated $171K sold.

Neville Rodie & Shaw first reported a position in WHWK in Q2 2018 and held it in 16 quarters. The position peaked at $415K in Q2 2018. 70 funds tracked by Wall St. Rank hold WHWK as of Q1 2023.

Neville Rodie & Shaw reported no remaining Whitehawk Therapeutics position as of Q1 2023 after selling out during the quarter.
Neville Rodie & Shaw sold 13,333 Whitehawk Therapeutics shares in Q1 2023, an estimated $171K.
Neville Rodie & Shaw first reported a position in Whitehawk Therapeutics in Q2 2018 and held it in 16 quarters.
Neville Rodie & Shaw's Whitehawk Therapeutics position peaked at $415K in Q2 2018.
70 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2023.

Based on Neville Rodie & Shaw's 13F filing for Q1 2023, filed 4 Apr 2023.